Cary Vance is recorded as Chairman at AVITA Medical, Inc. (RCEL) since August 7, 2025, Board Member at AVITA Medical, Inc. (RCEL) since January 1, 2023 and CEO at AVITA Medical, Inc. (RCEL). The newest filing on record that lists Cary Vance as CEO and Board Member at AVITA Medical, Inc. (RCEL) is dated April 22, 2026. AVITA Medical, Inc. reported in an 8-K filed May 1, 2026 that Cary Vance was appointed President and Chief Executive Officer. AVITA Medical, Inc. reported in an 8-K filed May 1, 2026 that Cary Vance was appointed President and Chief Executive Officer, effective April 30, 2026. AVITA Medical, Inc. reported in an 8-K filed October 17, 2025 that Cary Vance was appointed Interim Chief Executive Officer, effective October 16, 2025. Equibles holds 6 filed executive changes naming Cary Vance; each is listed under recent activity with its source filing. The proxy statement of AVITA Medical, Inc. reports total compensation of $278,053 for Cary Vance in fiscal 2025, including a base salary of $137,475. Disclosed compensation is on record for 2 fiscal years. Cary Vance has spoken on 4 earnings calls across 1 company, most recently for AVITA Medical, Inc. on August 6, 2026. AVITA Medical, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at AVITA Medical, Inc. includes Jan Stern Reed (Chairman and Board Member), David O'Toole (CFO), David O’Toole (CFO) and 7 others.
“AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately.”
AVITA Medical, Inc. Form 8-K, filed May 1, 2026
· Read the filing
“On April 29, 2026, the Board of Directors (the “Board”) of AVITA Medical, Inc (the "Company") appointed Cary Vance as President and Chief Executive Officer ("CEO"), effective April 30, 2026 (the “Effective Date”).”
AVITA Medical, Inc. Form 8-K, filed May 1, 2026
· Read the filing
Cary Vance on recent calls
“As you saw in our press release today, we delivered strong revenue growth in the second quarter of $21.7 million, up 18% year-over-year and 13% sequentially.”
“Before we begin, I would like to remind you that this call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.”
“Before we get into the numbers, I wanna start by coming back to how we closed the last call. In Q3, I ended with three priorities, driving disciplined execution, refining our commercial focus, and positioning a VITA for growth in 2026.”
“As this is my first earnings call as Interim CEO, I want to begin by saying how much I appreciate the opportunity to speak directly with our investors, employees, and clinical partners who make AVITA's mission to transform acute wound care possible.”
